The Effect of Semaglutide on Cardiovascular Markers and Liver Function

NCT06301191 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether semaglutide, a medication for type 2 diabetes, affects heart and liver health in adults with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Type Observational

Participants 50 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2022-03 · est. completion 2024-05

Where 1 site · Greece

What this study is testing ClinicalTrials.gov NCT06301191 ↗

Description as written by the study sponsor.

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

Treatments tested

Semaglutide, 1.0 mg/mL Drug

Semaglutide, 1.0 mg/mL
Dipeptidyl Peptidase 4 inhibitor Drug

Dipeptidyl Peptidase 4 inhibitor

Main thing measured	Comparison of arterial stiffness markers difference among treatment groups
Sponsor	Attikon Hospital
Conditions studied	Diabetes Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06301191 ↗